March 16th 2023
Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Robert J. Motzer, MD, on the Possible Impact of a Phase 3 Trial for Advanced ccRCCMarch 7th 2021
The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.
Robert J. Motzer, MD, on a Phase 3 Trial Evaluating MK-6482 Plus Lenvatinib Versus Cabozantinib for Advanced ccRCCMarch 4th 2021
The medical oncologist at Memorial Sloan Kettering Cancer Center highlighted what clinicians treating patients with advanced ccRCC should understand about this trial in progress.
Michael Szarek, PhD, on the Next Steps for Tivozanib in Patients with Advanced RCCMarch 1st 2021
An analysis revealed that as a third- or fourth-line treatment for advanced renal cell carcinoma, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.
Michael Szarek, PhD, on the Outcomes of a Q-TWiST Analysis From the Phase 3 TIVO-3 StudyFebruary 27th 2021
An analysis revealed that as a third- or fourth-line treatment for RCC, tivozanib significantly increased Q-TWiST compared with sorafenib, primarily through an increase in TWiST.
Phase 2 MERECA Trial Continues to Show Promise for Ilixadencel-Sunitinib Combination for mRCCFebruary 26th 2021
“These updated results from the phase 2 MERECA trial underscore the positive impact on overall survival that ilixadencel may achieve for [patients with kidney cancer],” said Sven Rohmann, MD, PhD.
Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ERFebruary 25th 2021
In the phase 3 CheckMate 9ER trial, investigators found that nivolumab plus cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously untreated advanced renal cell carcinoma.
Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCCFebruary 24th 2021
In the CheckMate 9ER trial, investigators compared combination treatment with nivolumab and cabozantinib versus sunitinib in patients with previously treated advanced renal cell carcinoma.
Adjuvant Pazopanib Does Not Improve Overall Survival for Patients With Locally Advanced RCCFebruary 22nd 2021
Follow-up data published in the European Association of Urology did not find a significant improvement in overall survival for patients with locally advanced renal cell carcinoma undergoing adjuvant pazopanib treatment.
CLEAR Study Readout Shows Survival Enhancement With Lenvatinib Plus Pembrolizumab Versus Sunitinib in Frontline RCCFebruary 14th 2021
Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.
Advanced RCC Shows Response to Frontline Nivolumab/Cabozantinib, Regardless of the Presence of Sarcomatoid FeaturesFebruary 13th 2021
Compared against sunitinib, nivolumab plus cabozantinib induced better outcomes in patients with advanced renal cell carcinoma and these results were seen in patients with and without sarcomatoid features.
Tivozanib Increased Time Without Symptoms of Disease, Toxicity for Patients with RCCFebruary 12th 2021
As third- or fourth-line therapy for patients with metastatic RCC, tivozanib hydrochloride demonstrated a statistically significant increased quality-adjusted time without symptoms of disease and toxicity compared with sorafenib.
Higher Starting Dose of Lenvatinib May Improve HR-QoL Among Patients with RCCFebruary 12th 2021
“Based on these findings, patients who received lenvatinib 18 mg starting dose had better quality of life and less severe symptoms than those who received lenvatinib 14 mg starting dose,” said Cristiane Decat Bergerot, PhD, MS, BS.
Improved OS Linked with First-line Immunotherapy for Patients with Advanced Non-Clear Cell RCCFebruary 11th 2021
Improvement in overall survival (OS) for patients with metastatic non–clear cell renal cell carcinoma (RCC) was linked with first-line treatment using immune checkpoint inhibitor–based regimens versus select targeted therapies
Lenvatinib/Everolimus Combo May Be Acceptable After Immunotherapy in Clear Cell RCCFebruary 11th 2021
Based on an exploratory analysis of a phase 2 trial, lenvatinib plus everolimus appears to be an acceptable treatment option for patients receiving prior immunotherapy for clear cell renal cell carcinoma.